STOCK TITAN

[SCHEDULE 13G/A] InspireMD, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rosalind Advisors, related funds and principals report material holdings in InspireMD (NSPR). The filing shows aggregate beneficial positions reported as 10,987,104 shares for several Reporting Persons, which the filing presents as approximately 9.4% of the class based on the S-3 share count and other per-entity percentages (Rosalind Master Fund L.P. 9.485,697 shares / 8.4%; Rosalind Opportunities Fund I L.P. 1,501,407 shares / 0.9%).

The reported totals include both currently outstanding common shares and shares issuable upon exercise of warrants (for example, Rosalind Advisors reports 3,905,743 common shares plus 7,081,361 shares issuable on warrants). The filing also discloses blocker provisions that prevent exercise of warrants to the extent doing so would push beneficial ownership above 9.99%, so the practical exercisable interest is lower than the raw issuable amount. The filing includes a certification that the holdings are held in the ordinary course of business and not for the purpose of changing control.

Rosalind Advisors, fondi correlati e i loro rappresentanti dichiarano partecipazioni rilevanti in InspireMD (NSPR). La comunicazione indica posizioni aggregate pari a 10.987.104 azioni per diversi soggetti segnalanti, che il documento presenta come circa 9,4% della classe basandosi sul conteggio S‑3 e sulle percentuali per entità (Rosalind Master Fund L.P. 9.485.697 azioni / 8,4%; Rosalind Opportunities Fund I L.P. 1.501.407 azioni / 0,9%).

I totali riportati comprendono sia le azioni ordinarie attualmente in circolazione sia le azioni esigibili mediante esercizio di warrant (ad esempio, Rosalind Advisors dichiara 3.905.743 azioni ordinarie più 7.081.361 azioni esigibili mediante warrant). Il documento segnala inoltre disposizioni "blocker" che impediscono l'esercizio dei warrant nella misura in cui ciò porterebbe la partecipazione beneficiaria oltre il 9,99%, pertanto l'interesse effettivamente esercitabile è inferiore all'ammontare lorda esigibile. È inclusa anche una certificazione che le partecipazioni sono detenute nell'ordinario corso dell'attività e non allo scopo di modificare il controllo.

Rosalind Advisors, fondos relacionados y los principales responsables informan participaciones materiales en InspireMD (NSPR). La presentación muestra posiciones beneficiosas agregadas de 10.987.104 acciones para varios sujetos informantes, que el documento presenta como aproximadamente 9,4% de la clase basándose en el recuento del S‑3 y en los porcentajes por entidad (Rosalind Master Fund L.P. 9.485.697 acciones / 8,4%; Rosalind Opportunities Fund I L.P. 1.501.407 acciones / 0,9%).

Los totales reportados incluyen tanto las acciones ordinarias actualmente en circulación como las acciones susceptibles de emitirse mediante el ejercicio de warrants (por ejemplo, Rosalind Advisors declara 3.905.743 acciones ordinarias más 7.081.361 acciones susceptibles de emitirse por warrants). La presentación también revela disposiciones "blocker" que impiden el ejercicio de los warrants en la medida en que ello llevaría la participación beneficiaria por encima del 9,99%, por lo que el interés ejercitable de facto es menor que la cantidad bruta susceptible de emitirse. El documento incluye además una certificación de que las participaciones se mantienen en el curso ordinario del negocio y no con el propósito de cambiar el control.

Rosalind Advisors와 관련 펀드 및 주요 인사들이 InspireMD(NSPR)에 대한 주요 보유를 보고했습니다. 해당 제출문서는 여러 보고 주체에 대해 총 10,987,104주의 수탁적 보유를 보고하며, S‑3 주식 수와 개체별 비율을 근거로 문서에서는 이를 대략 전체의 9.4%로 제시합니다(예: Rosalind Master Fund L.P. 9,485,697주 / 8.4%; Rosalind Opportunities Fund I L.P. 1,501,407주 / 0.9%).

보고된 합계에는 현재 발행된 보통주와 워런트 행사로 발행 가능한 주식이 모두 포함되어 있습니다(예: Rosalind Advisors는 3,905,743주의 보통주와 7,081,361주의 워런트 행사로 발행 가능한 주식을 보고함). 제출문서는 또한 보유 지분이 9.99%를 초과하지 않도록 워런트 행사를 제한하는 "블로커(blocker) 조항"을 공개하고 있어, 실제로 행사 가능한 이익은 원시 발행 가능 수량보다 적습니다. 제출문서에는 또한 해당 보유가 사업의 통상적 범위에서 보유되고 있으며 지배권 변경을 목적으로 하지 않았다는 인증이 포함되어 있습니다.

Rosalind Advisors, des fonds liés et des dirigeants déclarent des participations substantielles dans InspireMD (NSPR). Le dépôt fait état de positions bénéficiaires agrégées de 10 987 104 actions pour plusieurs personnes déclarante, que le document présente comme environ 9,4 % de la catégorie sur la base du décompte S‑3 et des pourcentages par entité (Rosalind Master Fund L.P. 9 485 697 actions / 8,4 % ; Rosalind Opportunities Fund I L.P. 1 501 407 actions / 0,9 %).

Les totaux déclarés incluent à la fois les actions ordinaires actuellement en circulation et les actions susceptibles d'être émises par exercice de warrants (par exemple, Rosalind Advisors déclare 3 905 743 actions ordinaires plus 7 081 361 actions susceptibles d'être émises par warrants). Le dépôt divulgue également des dispositions dites « blocker » empêchant l'exercice des warrants dans la mesure où cela porterait la participation bénéficiaire au‑dessus de 9,99 %, de sorte que l'intérêt effectivement exercable est inférieur au montant brut susceptible d'être émis. Le document comprend en outre une certification indiquant que les participations sont détenues dans le cours normal des affaires et non dans le but de modifier le contrôle.

Rosalind Advisors, verbundene Fonds und leitende Personen melden wesentliche Beteiligungen an InspireMD (NSPR). Die Einreichung weist aggregierte wirtschaftliche Positionen von 10.987.104 Aktien für mehrere meldende Personen aus, die das Dokument auf Grundlage der S‑3‑Aktienzahl und der einzelnen Anteilsprozentsätze als etwa 9,4% der Klasse darstellt (Rosalind Master Fund L.P. 9.485.697 Aktien / 8,4%; Rosalind Opportunities Fund I L.P. 1.501.407 Aktien / 0,9%).

Die gemeldeten Summen umfassen sowohl die derzeit ausstehenden Stammaktien als auch Aktien, die durch Ausübung von Warrants ausgebbar wären (z. B. meldet Rosalind Advisors 3.905.743 Stammaktien zuzüglich 7.081.361 Aktien, die durch Warrants ausübbar wären). Die Einreichung offenbart zudem "Blocker"-Bestimmungen, die die Ausübung von Warrants verhindern, soweit dadurch die wirtschaftliche Beteiligung über 9,99% steigen würde; damit ist das praktisch ausübungsfähige Interesse geringer als die brutto ausübbaren Stückzahl. Ebenfalls enthalten ist eine Bescheinigung, dass die Positionen im gewöhnlichen Geschäftsbetrieb gehalten werden und nicht zum Zweck einer Kontrolländerung.

Positive
  • Material disclosure of beneficial ownership above 5% by Rosalind entities and named principals, meeting SEC reporting standards
  • Detailed breakdown between currently held common shares and shares issuable on warrants, improving investor transparency
  • Certification states holdings are in the ordinary course of business and not for the purpose of changing control
Negative
  • Blocker provisions prevent exercise of warrants beyond 9.99%, limiting the practical increase in ownership despite large issuable amounts
  • Inconsistent bases for percent calculations are cited (different outstanding share counts from an S-3 and the issuer's 10-K), creating ambiguity about the exact percentage ownership

Insights

TL;DR: A disclosed stake near 9.4% is material and includes significant warrant exposure, but blockers limit near-term dilution.

The Schedule 13G/A shows the Rosalind group and named principals reporting beneficial positions that cross the 5% materiality threshold, with several reporting persons listing 10,987,104 shares (9.4%). Importantly, the reported position is a mix of issued shares and 7+ million shares issuable on warrants for some entities. Warrant blocker provisions restricting exercise above 9.99% mean the effective, exercisable ownership is constrained, reducing immediate dilution or control shifts. For analysts, the filing is material as it signals a significant investor position and potential future conversion dynamics, but the blocker materially limits short-term upside from warrant exercises.

TL;DR: Disclosure is thorough on holdings and intent; blocker language and inconsistent share bases create governance and clarity issues for investors.

The filing provides clear identification of reporting parties, vote/dispositive power allocations, and a certification that holdings are not intended to change control. That transparency is positive for governance. However, the filing references different outstanding share counts (a figure tied to an S-3 and a figure tied to the issuer's 10-K) when computing percentages, creating ambiguity about the precise ownership percentage investors should use. The existence of blocker provisions limits immediate conversion rights, which is governance-relevant because it constrains potential influence from warrant conversion despite large issuable amounts.

Rosalind Advisors, fondi correlati e i loro rappresentanti dichiarano partecipazioni rilevanti in InspireMD (NSPR). La comunicazione indica posizioni aggregate pari a 10.987.104 azioni per diversi soggetti segnalanti, che il documento presenta come circa 9,4% della classe basandosi sul conteggio S‑3 e sulle percentuali per entità (Rosalind Master Fund L.P. 9.485.697 azioni / 8,4%; Rosalind Opportunities Fund I L.P. 1.501.407 azioni / 0,9%).

I totali riportati comprendono sia le azioni ordinarie attualmente in circolazione sia le azioni esigibili mediante esercizio di warrant (ad esempio, Rosalind Advisors dichiara 3.905.743 azioni ordinarie più 7.081.361 azioni esigibili mediante warrant). Il documento segnala inoltre disposizioni "blocker" che impediscono l'esercizio dei warrant nella misura in cui ciò porterebbe la partecipazione beneficiaria oltre il 9,99%, pertanto l'interesse effettivamente esercitabile è inferiore all'ammontare lorda esigibile. È inclusa anche una certificazione che le partecipazioni sono detenute nell'ordinario corso dell'attività e non allo scopo di modificare il controllo.

Rosalind Advisors, fondos relacionados y los principales responsables informan participaciones materiales en InspireMD (NSPR). La presentación muestra posiciones beneficiosas agregadas de 10.987.104 acciones para varios sujetos informantes, que el documento presenta como aproximadamente 9,4% de la clase basándose en el recuento del S‑3 y en los porcentajes por entidad (Rosalind Master Fund L.P. 9.485.697 acciones / 8,4%; Rosalind Opportunities Fund I L.P. 1.501.407 acciones / 0,9%).

Los totales reportados incluyen tanto las acciones ordinarias actualmente en circulación como las acciones susceptibles de emitirse mediante el ejercicio de warrants (por ejemplo, Rosalind Advisors declara 3.905.743 acciones ordinarias más 7.081.361 acciones susceptibles de emitirse por warrants). La presentación también revela disposiciones "blocker" que impiden el ejercicio de los warrants en la medida en que ello llevaría la participación beneficiaria por encima del 9,99%, por lo que el interés ejercitable de facto es menor que la cantidad bruta susceptible de emitirse. El documento incluye además una certificación de que las participaciones se mantienen en el curso ordinario del negocio y no con el propósito de cambiar el control.

Rosalind Advisors와 관련 펀드 및 주요 인사들이 InspireMD(NSPR)에 대한 주요 보유를 보고했습니다. 해당 제출문서는 여러 보고 주체에 대해 총 10,987,104주의 수탁적 보유를 보고하며, S‑3 주식 수와 개체별 비율을 근거로 문서에서는 이를 대략 전체의 9.4%로 제시합니다(예: Rosalind Master Fund L.P. 9,485,697주 / 8.4%; Rosalind Opportunities Fund I L.P. 1,501,407주 / 0.9%).

보고된 합계에는 현재 발행된 보통주와 워런트 행사로 발행 가능한 주식이 모두 포함되어 있습니다(예: Rosalind Advisors는 3,905,743주의 보통주와 7,081,361주의 워런트 행사로 발행 가능한 주식을 보고함). 제출문서는 또한 보유 지분이 9.99%를 초과하지 않도록 워런트 행사를 제한하는 "블로커(blocker) 조항"을 공개하고 있어, 실제로 행사 가능한 이익은 원시 발행 가능 수량보다 적습니다. 제출문서에는 또한 해당 보유가 사업의 통상적 범위에서 보유되고 있으며 지배권 변경을 목적으로 하지 않았다는 인증이 포함되어 있습니다.

Rosalind Advisors, des fonds liés et des dirigeants déclarent des participations substantielles dans InspireMD (NSPR). Le dépôt fait état de positions bénéficiaires agrégées de 10 987 104 actions pour plusieurs personnes déclarante, que le document présente comme environ 9,4 % de la catégorie sur la base du décompte S‑3 et des pourcentages par entité (Rosalind Master Fund L.P. 9 485 697 actions / 8,4 % ; Rosalind Opportunities Fund I L.P. 1 501 407 actions / 0,9 %).

Les totaux déclarés incluent à la fois les actions ordinaires actuellement en circulation et les actions susceptibles d'être émises par exercice de warrants (par exemple, Rosalind Advisors déclare 3 905 743 actions ordinaires plus 7 081 361 actions susceptibles d'être émises par warrants). Le dépôt divulgue également des dispositions dites « blocker » empêchant l'exercice des warrants dans la mesure où cela porterait la participation bénéficiaire au‑dessus de 9,99 %, de sorte que l'intérêt effectivement exercable est inférieur au montant brut susceptible d'être émis. Le document comprend en outre une certification indiquant que les participations sont détenues dans le cours normal des affaires et non dans le but de modifier le contrôle.

Rosalind Advisors, verbundene Fonds und leitende Personen melden wesentliche Beteiligungen an InspireMD (NSPR). Die Einreichung weist aggregierte wirtschaftliche Positionen von 10.987.104 Aktien für mehrere meldende Personen aus, die das Dokument auf Grundlage der S‑3‑Aktienzahl und der einzelnen Anteilsprozentsätze als etwa 9,4% der Klasse darstellt (Rosalind Master Fund L.P. 9.485.697 Aktien / 8,4%; Rosalind Opportunities Fund I L.P. 1.501.407 Aktien / 0,9%).

Die gemeldeten Summen umfassen sowohl die derzeit ausstehenden Stammaktien als auch Aktien, die durch Ausübung von Warrants ausgebbar wären (z. B. meldet Rosalind Advisors 3.905.743 Stammaktien zuzüglich 7.081.361 Aktien, die durch Warrants ausübbar wären). Die Einreichung offenbart zudem "Blocker"-Bestimmungen, die die Ausübung von Warrants verhindern, soweit dadurch die wirtschaftliche Beteiligung über 9,99% steigen würde; damit ist das praktisch ausübungsfähige Interesse geringer als die brutto ausübbaren Stückzahl. Ebenfalls enthalten ist eine Bescheinigung, dass die Positionen im gewöhnlichen Geschäftsbetrieb gehalten werden und nicht zum Zweck einer Kontrolländerung.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth in Row 11 of the cover page for each Reporting Person is based upon 41,720,662 shares of common stock outstanding of the Issuer as of August 1, 2025, in accordance with the S-3 filed on August 1st. However, as more fully described in Item 4, the securities reported in rows 6, 8, and 9 show the number of shares of Common Stock that would be issuable upon exercise of such reported securities and do not give effect to blocker provisions. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows 6, 8, and 9. (6) 3,905,743 shares of Common Stock 7,081,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)3,905,743 shares of Common Stock 7,081,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)3,905,743 shares of Common Stock 7,081,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)3,508,336 shares of Common Stock 5,977,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)397,407 shares of Common Stock 1,104,000 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Rosalind Advisors, Inc.
Signature:Steven Salamon
Name/Title:President
Date:08/11/2025
SALAMON STEVEN A J
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:08/11/2025
Aharon Gil
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:08/11/2025
Rosalind Master Fund L.P.
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:08/11/2025
Rosalind Opportunities Fund I L.P.
Signature:Steven Salamon
Name/Title:Director, Rosalind Opportunities Fund I GP. Inc. (as General Partners to Rosalind Opportunities Fund I)
Date:08/11/2025

FAQ

What stake does Rosalind Advisors report in InspireMD (NSPR)?

Rosalind Advisors reports an aggregate beneficial position of 10,987,104 shares, presented as approximately 9.4% of the class (this total includes both currently outstanding shares and shares issuable upon exercise of warrants).

How many shares and warrants are included in Rosalind's reported position?

The filing discloses specific components: for example, Rosalind Advisors lists 3,905,743 common shares plus 7,081,361 shares issuable on warrants as part of its reported total.

Do the reported warrants allow immediate conversion to increase ownership?

No. The filing states blocker provisions9.99%, so many issuable warrants cannot be exercised currently.

Which entities and individuals are the reporting persons in this filing?

Reporting persons include Rosalind Advisors, Inc., Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P., and principals Steven Salamon and Gilad Aharon.

Are these holdings reported as intended to change control of InspireMD (NSPR)?

The filing includes a certification stating the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer, aside from nomination activities under the cited rule.

Why do percentage figures in the filing differ?

The filing references different outstanding share counts when computing percentages (a share count from an S-3 and a share count from the issuer's 10-K), which explains the differing percentage presentations.
Inspiremd

NASDAQ:NSPR

NSPR Rankings

NSPR Latest News

NSPR Latest SEC Filings

NSPR Stock Data

100.13M
30.13M
22.45%
40.55%
0.31%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MIAMI